Skip to main content
Search

Biosimilars in inflammatory bowel disease: copycats or genuine replacements?

Published on April 28, 2021   47 min

A selection of talks on Immunology

Please wait while the transcript is being prepared...
0:00
Hello everybody, my name is Raj Eri. I'm an associate professor at the University of Tasmania, Australia, at the School of Health Sciences where I teach biochemistry and immunology. I've been a scientist working in the field of inflammatory bowel disease for a long time. Today, we're going to be talking about an exciting development in the inflammatory bowel disease area. We're going to discuss biosimilars, we're talking about potential drugs that can replace the existing biologicals. Today I would like to discuss biosimilars and ask: are they just copycats aiming to get a piece of the pie in the lucrative biological market, or are these genuine replacements that will reduce costs and provide equal benefit to inflammatory bowel disease patients?
1:01
In this particular lecture, I'll be covering the following aspects. Firstly, introducing the biosimilars. People are used to the biologicals, now we want to define what we mean by this new group of drugs called 'biosimilars'. The comparison will be discussed. Then the use of biosimilars in inflammatory bowel disease; the aspect about coverage of biosimilars, how they are being utilized in inflammatory bowel disease clinically, and what the studies are that have been carried out. Then we'll conclude with some of the concerns, and discuss the future for this biosimilar industry. This is the talk plan with which we'll go ahead in this particular lecture.
Show
Hide

Biosimilars in inflammatory bowel disease: copycats or genuine replacements?

Embed in course/own notes